SGAI Predictable
De-Risking 

The Challenge: Navigating Risk in Healthcare Investments

​

The healthcare and life sciences sectors present a landscape of immense opportunity, but also one of staggering risk. Startups in these fields face a gauntlet of challenges, including complex regulatory hurdles, uncertain market access, high capital inefficiency, and fragmented operational execution. These factors contribute to alarmingly high failure rates, with numerous sources indicating that a vast majority of ventures do not succeed in the long term.

Our research confirms the severity of this issue. Multiple analyses from credible institutions and publications converge on a stark reality: the failure rate for healthcare and life sciences startups is exceptionally high. For instance, various reports place the long-term failure rate for life science and biotech startups at approximately 90% [1, 2, 3]. More specifically, studies show that a significant portion of these failures occur within the first five years of operation [2, 4]. The development costs associated with bringing a new medical device to market further underscore the financial risks involved, with estimates ranging from $31 million to over $94 million, depending on the complexity and regulatory pathway [5, 6].

This high-risk environment translates into longer development timelines, inflated costs, and uncertain exit prospects, creating persistent headwinds for venture capital funds and their limited partners. The challenge is not a lack of innovative science, but a deficiency in the commercial and operational expertise required to navigate the path to market successfully.